🔍
Disruption of p53 in Human Cancer Cells Alters the Responses to Therapeutic Agents
Case ID:
C03920
Report of Invention:
7/25/2001
Web Published:
10/7/2014
C03920: Disruption of p53 in Human Cancer Cells Alters the Responses to Therapeutic Agents
Technical Details:
p53 knockout in human colorectal cancer cell line HCT116. Details are described in the paper by Bunz et al., 1999
Looking for Partners:
The p53 gene is inactivated in the majority of human cancers. JHU scientists determined that p53 knockout cell lines have altered responses to therapeutic agents, being sensitized to DNA damaging agents but resistant to anti-metabolite 5-fluorouracil. This novel knock-out line provides the basis for a new drug screen to identify compounds that specifically kill cells with p53 mutations.
Patent Information:
Title
App Type
Country
Serial No.
Patent No.
File Date
Issued Date
Expire Date
Patent Status
Direct Link:
https://jhu.technologypublisher.com/technology/16221
Inventors:
Category(s):
Clinical and Disease Specializations, Clinical and Disease Specializations > Gastroenterology, Clinical and Disease Specializations > Oncology > Colorectal Cancer, Technology Classifications > Research Tools > Cell Lines, Clinical and Disease Specializations > Oncology, Technology Classifications > Research Tools,
Get custom alerts for techs in these categories/from these inventors:
Subscribe for JHTV Updates
For Information, Contact:
Jeanine Pennington
jpennin5@jhmi.edu
410-614-0300
Save This Technology:
Bookmark this page
Download as PDF
JHTV Home
|
Search
|
Login/Subscribe
2017 - 2022 © Johns Hopkins Technology Ventures. All Rights Reserved. Powered by
Inteum